February 2025
Supernus Pharmaceuticals’ Stock Plummets as Phase 2b Depression Drug Trial Fails to Meet Primary Endpoint
Supernus Pharmaceuticals, SPN-820, treatment-resistant depression, clinical trial failure, stock decline, placebo effect
RFK Jr. Backtracks on Vaccine Pledge, Announces Review of Childhood Immunization Schedule
Robert F. Kennedy Jr., HHS Secretary, childhood vaccine schedule, review, controversy, public health, measles outbreak, Senate confirmation
GSK’s Penmenvy Approved: New 5-in-1 Meningococcal Vaccine Enters U.S. Market
Penmenvy, GSK, meningococcal vaccine, FDA approval, 5-in-1 vaccine, MenABCWY, invasive meningococcal disease (IMD)
Major Budget Cuts and Layoffs Hit US Health Agencies: Impacts on CDC, NIH, and Public Health
healthcare budget cuts, CDC layoffs, NIH funding reduction, public health impact, Trump administration, federal workforce reduction, medical research funding
Bavarian Nordic’s Vimkunya Approved by FDA as First Chikungunya Vaccine for Ages 12 and Up
Vimkunya, chikungunya vaccine, Bavarian Nordic, FDA approval, virus-like particle vaccine, adolescents, travelers
AI-Guided Cardiac Ablation Outperforms Standard Treatment for Persistent Atrial Fibrillation
Volta Medical, artificial intelligence, cardiac ablation, atrial fibrillation, TAILORED-AF trial, pulmonary vein isolation, electrophysiology
FDA Approves Ono Pharmaceutical’s Romvimza for Rare Joint Tumor
Romvimza, tenosynovial giant cell tumor (TGCT), FDA approval, Ono Pharmaceutical, Deciphera acquisition, kinase inhibitor, rare cancer treatment
Novo Nordisk Pursues $830 Million Fraud Claim Against KBP Biosciences Over Failed Hypertension Drug
Novo Nordisk, KBP Biosciences, ocedurenone, fraud, asset freeze, clinical trial failure, hypertension drug, arbitration
Biogen and Stoke Therapeutics Partner on Promising Dravet Syndrome Treatment
Biogen, Stoke Therapeutics, zorevunersen, Dravet syndrome, antisense oligonucleotide, rare epilepsy, drug development, pharmaceutical partnership
Solid Biosciences’ DMD Gene Therapy Shows Promising Early Results, Driving Stock Surge
Duchenne muscular dystrophy (DMD), gene therapy, SGT-003, microdystrophin, clinical trial, stock surge, Solid Biosciences